Alternative mRNA modification lets ribosomes move nearly twice as fast
In a new study, scientists from Johns Hopkins Medicine report that an experimental mRNA-based platform has the potential to help deliver next-generation mRNA therapeutics, including vaccines to fight infectious diseases, cancer and autoimmune conditions, faster and more efficiently than the industry standard.
A new study from Johns Hopkins Medicine has found that an experimental mRNA platform using N4-acetylcytidine (ac4C) allows ribosomes to move nearly twice as fast as the industry-standard mRNA platform, N1-Methylpseudouridine (m1Ψ). This faster ribosome movement may lead to more efficient mRNA therapeutics, including vaccines, that require smaller doses and produce higher levels of therapeutic proteins.
In experiments with human dendritic cells and mouse liver cells, researchers observed that ribosomes on ac4C-modified mRNA traveled faster, preventing traffic jams and premature termination of protein production. These results suggest that ac4C could enhance mRNA translation efficiency and improve the effectiveness of mRNA-based therapies.
Written by urgent.news from Phys.org's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
